HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCPC: Cosmetic Legislation A Long Shot In 2016, But Objectives Are Clear

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Council isn't counting on the Personal Care Products Safety Act to pass in 2016, but compromise efforts to reconcile that bill and the Cosmetic Modernization Amendments supported by small business could be the ticket to reform in the 115th Congress, the trade group suggests. PCPC execs discussed the current legislative landscape at the group's annual meeting in Palm Beach, Florida.

You may also be interested in...



PCPC Statement On Cosmetics Reform Legislation Hints At Potential Compromises

The Personal Care Products Council outlines a list of “principles” that it believes should guide legislation to update cosmetics regulations. Many of its priorities could be seen as aligning more closely with reintroduced House legislation than the less industry-friendly Personal Care Products Safety Act in the previous Senate, signaling a possible change in strategic direction at PCPC under the new Administration.

All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests

During update on user fee discussions with industry to support FDA's OTC monograph program work, CDER officials say "industry and public would suffer" absent new fees.

All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests

During update on user fee discussions with industry to support FDA's OTC monograph program work, CDER officials say "industry and public would suffer" absent new fees.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel